Relationship between serum sB7-H3 and treatment response and prognosis of patients with non-musculoinvasive bladder cancer after TUBRT intravesical injection of BCG vaccine
Objective To investigate the relationship between serum soluble B7 homologous 3(sB7-H3)and the response and prognosis of intracystial BCG injection after transurethral resection of bladder tumor(TURBT)in patients with non-muscle invasive bladder cancer.Methods One hundred and six patients with non-muscular invasive bladder cancer who received standard TURBT and postoperative adjuvant intravesical BCG infusion at the Second People's Hospital of Huai'an from March 2018 to March 2021 were collected.Serum samples were collected 3 days before BCG induction therapy(T1),2 times after BCG induction therapy(T2),4 times after BCG induction therapy(T3),and after completion of BCG induction therapy(T4),and serum sB7-H3 levels were determined by enzym-linked immunosorbent assay(ELISA).The efficacy of serum sB7-H3 as a biomarker of BCG response and prognosis was evaluated using receiver operating characteristic(ROC)curves and Cox proportional hazard regression models.Results Thirty-five patients did not respond to treatment.At T1,T3 and T4 time points,serum sB7-H3 levels were lower in the treatment response group(P<0.05).Only(T4-T1)serum sB7-H3 was different between patients who responded to treatment and those who did not(P<0.05).The results of binary multi-factor logistics model showed that serum sB7-H3(T1)and the change value of sB7-H3(T4-T1)were the factors affecting the treatment response(P<0.05).During follow-up,37 patients had disease progression and 35 had tumor-specific death.Univariate and multivariate Cox results showed that sB7-H3(T1)and sB7-H3 change value(T4-T1)were the factors affecting disease-free survival(DFS)and tumor-specific survival(DSS)in patients with non-muscular invasive bladder cancer(P<0.05).Kaplan-Meier curves show that sB7-H3(T1)and sB7-H3 variations(T4-T1)are associated with shorter DSS and DFS.Conclusion Serum sB7-H3 level before and during induction therapy can be used as a predictor of the response to BCG immunotherapy in patients with non-muscular invasive bladder cancer,and high serum sB7-H3 level is a predictor of poor prognosis.
NETL
NSTL
万方数据
